- Home
- SNGX vs VRAX Comparison
SNGX vs VRAX Comparison
Compare SNGX & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- VRAX
- Stock Information
- Founded
- SNGX 1987
- VRAX 2013
- Country
- SNGX United States
- VRAX United Kingdom
- Employees
- SNGX N/A
- VRAX N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SNGX Health Care
- VRAX Health Care
- Exchange
- SNGX Nasdaq
- VRAX Nasdaq
- Market Cap
- SNGX 7.4M
- VRAX 7.3M
- IPO Year
- SNGX 1987
- VRAX 2022
- Fundamental
- Price
- SNGX $2.35
- VRAX $1.80
- Analyst Decision
- SNGX
- VRAX
- Analyst Count
- SNGX 0
- VRAX 0
- Target Price
- SNGX N/A
- VRAX N/A
- AVG Volume (30 Days)
- SNGX 621.7K
- VRAX 230.2K
- Earning Date
- SNGX 03-14-2025
- VRAX 02-05-2025
- Dividend Yield
- SNGX N/A
- VRAX N/A
- EPS Growth
- SNGX N/A
- VRAX N/A
- EPS
- SNGX N/A
- VRAX N/A
- Revenue
- SNGX $364,183.00
- VRAX $84,872.00
- Revenue This Year
- SNGX N/A
- VRAX $5,169.18
- Revenue Next Year
- SNGX $76.64
- VRAX $66.97
- P/E Ratio
- SNGX N/A
- VRAX N/A
- Revenue Growth
- SNGX N/A
- VRAX 7.03
- 52 Week Low
- SNGX $1.83
- VRAX $0.60
- 52 Week High
- SNGX $14.88
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- SNGX 38.58
- VRAX 43.63
- Support Level
- SNGX $2.16
- VRAX $1.56
- Resistance Level
- SNGX $2.63
- VRAX $1.86
- Average True Range (ATR)
- SNGX 0.17
- VRAX 0.20
- MACD
- SNGX 0.01
- VRAX -0.05
- Stochastic Oscillator
- SNGX 36.54
- VRAX 32.05
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.